{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:36:20Z","timestamp":1784039780881,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>We describe the epidemiology of cancer after kidney transplantation (KTx), investigating its risk factors and impact on therapeutic management and survival in KTx recipients (KTRs). The association between modification of immunosuppressive (IS) therapy after cancer and survival outcomes was analyzed. We collected data from 930 KTRs followed for 7 [1\u201319]\u00a0years. The majority of KTRs received KTx from a deceased donor (84%). In total, 74% of patients received induction therapy with basiliximab and 26% with ATG. Maintenance therapy included steroids, calcineurin inhibitors, and mycophenolate. Patients with at least one cancer (CA+) amounted to 19%. NMSC was the most common tumor (55%). CA+ were older and had a higher BMI. Vasculitis and ADPKD were more prevalent in CA+. ATG was independently associated with CA+ and was related to earlier cancer development in survival and competing risk analyses (<jats:italic>p<\/jats:italic> = 0.01 and &amp;lt;0.0001; basiliximab 89 \u00b1 4 vs<jats:italic>.<\/jats:italic> ATG 40 \u00b1 4\u00a0months). After cancer diagnosis, a significant prognostic impact was derived from the shift to mTOR inhibitors compared to a definitive IS drug suspension (<jats:italic>p<\/jats:italic> = 0.004). Our data confirm the relevance of cancer as a complication in KTRs with ATG as an independent risk factor. An individualized choice of IS to be proposed at the time of KTx is crucial in the prevention of neoplastic risk. Finally, switching to mTORi could represent an important strategy to improve patient survival.<\/jats:p>","DOI":"10.3389\/ti.2024.13220","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:11:06Z","timestamp":1724127066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center"],"prefix":"10.3389","volume":"37","author":[{"given":"Giulia Vanessa","family":"Re Sart\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilietta","family":"Brigati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Campise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Regalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Verdesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Pisacreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Gallieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in Kidney Transplant Recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Law Met Al. Cancer Incidence Before and After Kidney Transplantation","volume":"296","author":"Vajdic","year":"","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and Site-Specific Cancer Mortality in Patients on Dialysis and After Kidney Transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer Incidence Among Canadian Kidney Transplant Recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transpl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/TP.0b013e3181ff1458","article-title":"Patient Survival After the Diagnosis of Cancer in Renal Transplant Recipients: A Nested Case-Control Study","volume":"90","author":"van de Wetering","year":"2010","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ijc.34787","article-title":"Cancer Mortality After Kidney Transplantation: A Multicenter Cohort Study in Italy","volume":"154","author":"Taborelli","year":"2023","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ajt.16825","article-title":"The Impact of Cancer on the Risk of Death With a Functioning Graft of Italian Kidney Transplant Recipients","volume":"22","author":"Taborelli","year":"2022","journal-title":"Am J Transpl"},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semnephrol.2022.01.003","article-title":"Emerging Concepts in Managing Malignancy in Kidney Transplant Patients","volume":"42","author":"Schreiber","year":"2022","journal-title":"Semin Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1093\/ndt\/gfac337","article-title":"Malignancy Risk in Kidney Transplant Recipients Exposed to Immunosuppression Pre-Transplant for the Treatment of Glomerulonephritis","volume":"38","author":"Massicotte-Azarniouch","year":"2023","journal-title":"Nephrol Dial Transpl"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3390\/jcm13071872","article-title":"Incidence, Risk Factors, and Outcomes of De Novo Malignancy Following Kidney Transplantation","volume":"13","author":"Chukwu","year":"2024","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in Cancer Incidence and Outcomes Among Kidney Transplant Recipients in the United States Over a Thirty-Year Period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00000658-192102000-00001","article-title":"Squamous-Cell Epithelioma of the Skin: A Study of 256 Cases","volume":"73","author":"Broders","year":"1921","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/cancers15041347","article-title":"Variation in Post-Transplant Cancer Incidence Among Italian Kidney Transplant Recipients Over a 25-Year Period","volume":"15","author":"Piselli","year":"","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/j.transproceed.2019.04.096","article-title":"De Novo Cancer Incidence and Prognosis After Kidney Transplantation: A Single Center Analysis","volume":"51","author":"Gioco","year":"2019","journal-title":"Transpl Proc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11614","DOI":"10.3389\/ti.2024.11614","article-title":"Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand","volume":"37","author":"Srisuwarn","year":"2024","journal-title":"Transpl Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/s0140-6736(05)80084-4","article-title":"Incidence of Non-Hodgkin Lymphoma in Kidney and Heart Transplant Recipients","volume":"342","author":"Opelz","year":"","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/ckj\/sfac013","article-title":"Cancer Among Kidney Transplant Recipients >20 Years After Transplantation: Post-Transplant Lymphoproliferative Disorder Remains the Most Common Cancer Type in the Ultra Long-Term","volume":"15","author":"Fuhrmann","year":"","journal-title":"Clin Kidney J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results","volume":"36","author":"Dantal","year":"","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15,183 Recipients","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transpl"},{"key":"B21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.V95842","article-title":"Relapse Rate, Renal Survival, and Cancer Morbidity in Patients With Wegener\u2019s Granulomatosis or Microscopic Polyangiitis With Renal Involvement","volume":"9","author":"Westman","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s10067-020-05055-x","article-title":"Cancer Risks Along the Disease Trajectory in Antineutrophil Cytoplasmic Antibody Associated Vasculitis","volume":"39","author":"Thet","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-01951-6","article-title":"Kidney Transplantation in Patients With ANCA-Associated Vasculitis Is Associated With a High Incidence of Post-Transplant Cancer","author":"Perna","year":"2024","journal-title":"J Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S1470-2045(16)30250-9","article-title":"Risk of Cancer in Patients With Polycystic Kidney Disease: A Propensity-Score Matched Analysis of a Nationwide, Population-Based Cohort Study","volume":"17","author":"Yu","year":"2016","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0158732","DOI":"10.1371\/journal.pone.0158732","article-title":"Independent Pre-Transplant Recipient Cancer Risk Factors After Kidney Transplantation and the Utility of G-Chart Analysis for Clinical Process Control","volume":"11","author":"Schrem","year":"","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/FTD.0000000000000820","article-title":"Tacrolimus Exposure in Obese Patients: and A Case-Control Study in Kidney Transplantation","volume":"43","author":"Robert","year":"","journal-title":"Ther Drug Monit"},{"key":"B27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3892\/ijo.2024.5667","article-title":"Impact of Obesity-Associated Myeloid-Derived Suppressor Cells on Cancer Risk and Progression (Review)","volume":"65","author":"Jim\u00e9nez-Cortegana","year":"2024","journal-title":"Int J Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e14121","DOI":"10.1111\/ctr.14121","article-title":"Induction Immunosuppression and the Risk of Incident Malignancies Among Older and Younger Kidney Transplant Recipients: A Prospective Cohort Study","volume":"34","author":"Wang","year":"2020","journal-title":"Clin Transpl"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the Type of Induction Immunosuppression With Posttransplant Lymphoproliferative Disorder, Graft Survival, and Patient Survival After Primary Kidney Transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/0886022X.2020.1759636","article-title":"Relationship Between Rabbit Anti-Thymocyte Globulin and Development of PTLD and Its Aggressive Form in Renal Transplant Population","volume":"42","author":"Ali","year":"2020","journal-title":"Ren Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/ajt.13092","article-title":"ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients","volume":"15","author":"Crepin","year":"2015","journal-title":"Am J Transpl"},{"key":"B33","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/ijc.32585","article-title":"Cancer Mortality in Kidney Transplant Recipients: An Australian and New Zealand Population-Based Cohort Study, 1980-2013","volume":"146","author":"Rosales","year":"","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival After a Cancer Diagnosis Among Solid Organ Transplant Recipients in the United States","volume":"125","author":"D\u2019Arcy","year":"2019","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A Multi-Center Study on Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients With Kidney Transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune Checkpoint Inhibitor Nephrotoxicity: What Do We Know and What Should We Do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ijc.31769","article-title":"Optimal Oncologic Management and mTOR Inhibitor Introduction Are Safe and Improve Survival in Kidney and Liver Allograft Recipients With De Novo Carcinoma","volume":"144","author":"Rousseau","year":"2019","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression With Mammalian Target of Rapamycin Inhibitor and Incidence of Post-Transplant Cancer in Kidney Transplant Recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/tri.13952","article-title":"Managing Immunosuppressive Therapy in Potentially Cured Post-Kidney Transplant Cancer (Excluding Non-Melanoma Skin Cancer): An Overview of the Available Evidence and Guidance for Shared Decision-Making","volume":"34","author":"Hellemans","year":"2021","journal-title":"Transpl Int"},{"key":"B41","doi-asserted-by":"publisher","first-page":"44833","DOI":"10.18632\/oncotarget.14908","article-title":"Conversion to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients With De Novo Cancers","volume":"8","author":"Cheung","year":"","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of Sirolimus on Malignancy and Survival After Kidney Transplantation: Systematic Review and Meta-Analysis of Individual Patient Data","volume":"349","author":"Knoll","year":"","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2215\/CJN.00190116","article-title":"Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients","volume":"11","author":"Badve","year":"","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:11:17Z","timestamp":1724127077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":43,"alternative-id":["10.3389\/ti.2024.13220"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.13220","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"13220"}}